DS‐8201a, a new HER2‐targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2‐positive gastric cancer T‐DM1 resistance
Naoki Takegawa(Kindai University), Junji Tsurutani(Kindai University)
Cited by 193
Related Papers
Tobacco components stimulate Akt-dependent proliferation and NFκB-dependent survival in lung cancer cells
|Carcinogenesis|2005|289
[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on <i>HER2</i> amplification
|International Journal of Cancer|2019|90